Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Shima

Showing results (241-250 of 262) with videos related to

Pageof 27
Sort By:
Physical Review Letters|October 4, 2005
Irradiation-induced magnetism in carbon nanostructuresS Talapatra, P G Ganesan, T Kim, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Factor IX inhibition and epitope localization of factor IX inhibitor antibodies in haemophilia B patients with anaphylactoid reactionsM Yamamoto, S Kamisue, Y Sawamoto, et al.
Thrombosis and Haemostasis|June 12, 1999
Identification of the binding site for an alloantibody to von Willebrand factor which inhibits binding to glycoprotein Ib within the amino-terminal region flanking the A1 domainM Shibata, M Shima, Y Fujimura, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 1, 1996
[Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII]M Shima, Y Sawamoto, M Kamisue, et al.
Blood|February 7, 2001
Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysisK Nogami, M Shima, J C Giddings, et al.
The Journal of Clinical Endocrinology and Metabolism|November 24, 1999
No enzyme activity of 25-hydroxyvitamin D3 1alpha-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestationS Kitanaka, A Murayama, T Sakaki, et al.
British Journal of Haematology|October 16, 1999
Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effectK Nogami, M Shima, H Nakai, et al.
Journal of Thrombosis and Haemostasis : JTH|April 17, 2014
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementationA Muto, K Yoshihashi, M Takeda, et al.
Journal of Thrombosis and Haemostasis : JTH|April 17, 2014
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementationA Muto, K Yoshihashi, M Takeda, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 30, 2016
Successful haemostatic management of replacement of the ascending aorta for type A acute aortic dissection in a patient with mild haemophilia BM Takeyama, K Nogami, Y Shida, et al.
Pageof 27

Showing results (241-250 of 262) with videos related to

Sort By:
Pageof 27
Physical Review Letters|October 4, 2005
Irradiation-induced magnetism in carbon nanostructuresS Talapatra, P G Ganesan, T Kim, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Factor IX inhibition and epitope localization of factor IX inhibitor antibodies in haemophilia B patients with anaphylactoid reactionsM Yamamoto, S Kamisue, Y Sawamoto, et al.
Thrombosis and Haemostasis|June 12, 1999
Identification of the binding site for an alloantibody to von Willebrand factor which inhibits binding to glycoprotein Ib within the amino-terminal region flanking the A1 domainM Shibata, M Shima, Y Fujimura, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 1, 1996
[Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII]M Shima, Y Sawamoto, M Kamisue, et al.
Blood|February 7, 2001
Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysisK Nogami, M Shima, J C Giddings, et al.
The Journal of Clinical Endocrinology and Metabolism|November 24, 1999
No enzyme activity of 25-hydroxyvitamin D3 1alpha-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestationS Kitanaka, A Murayama, T Sakaki, et al.
British Journal of Haematology|October 16, 1999
Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effectK Nogami, M Shima, H Nakai, et al.
Journal of Thrombosis and Haemostasis : JTH|April 17, 2014
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementationA Muto, K Yoshihashi, M Takeda, et al.
Journal of Thrombosis and Haemostasis : JTH|April 17, 2014
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementationA Muto, K Yoshihashi, M Takeda, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 30, 2016
Successful haemostatic management of replacement of the ascending aorta for type A acute aortic dissection in a patient with mild haemophilia BM Takeyama, K Nogami, Y Shida, et al.
Pageof 27